Pharma BD Deal Intelligence
Takeda Pharmaceutical Company Ltd. / Nabla Bio, Inc.
2025 · Co-Development · $1.0B · Complete
Takeda entered a second multi-year research collaboration with Nabla Bio to apply Nabla's Joint Atomic Model (JAM) generative protein-design platform to design de novo antibodies, multispecifics and other custom therapeutics across multiple early-pipeline Takeda targets. Nabla receives double-digit-millions in upfront and research cost payments (amount not disclosed) and is eligible for success-based payments the companies state may exceed $1 billion in total, plus royalties. Expands a partnership first struck in 2022.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 14, 2025
- Deal value $1.0B
- Deal type Co-Development
- Therapeutic area Multiple
- Indications Undisclosed (multiple early-pipeline targets)
- Key assets De novo antibodies and multispecifics designed on the Joint Atomic Model (JAM) platform
- Mechanism AI-driven de novo protein/antibody design
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Takeda Pharmaceutical Company Ltd. deals · Multiple deals